Trial Profile
A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Jul 2022
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic retinopathy
- Focus Registrational; Therapeutic Use
- Acronyms PANORAMA
- Sponsors Regeneron Pharmaceuticals
- 29 Jun 2022 According to a Regeneron pharmaceuticals media release, the company announced that U.S. Food and Drug Administration (FDA) has accepted for review the EYLEA (aflibercept) Injection supplemental Biologics License Application (sBLA) for an every 16-week 2 mg dosing regimen (after initial monthly doses) in patients with diabetic retinopathy (DR). The target action date for the FDA decision is February 28, 2023.
- 08 Feb 2020 According to a Regeneron pharmaceuticals media release, Charles C. Wykoff is an investigator for this trial.
- 08 Feb 2020 Results presented in a Regeneron pharmaceuticals Media Release.